检验医学与临床
檢驗醫學與臨床
검험의학여림상
JOURNAL OF LABORATORY MEDICINE AND CLINICAL SCIENCES
2014年
21期
3008-3010
,共3页
β2 受体激动剂%抗胆碱能药物%β2 受体激动剂联合抗胆碱能药物%儿童哮喘%急诊
β2 受體激動劑%抗膽堿能藥物%β2 受體激動劑聯閤抗膽堿能藥物%兒童哮喘%急診
β2 수체격동제%항담감능약물%β2 수체격동제연합항담감능약물%인동효천%급진
β2 receptor agonists%anticholinergic drugs%β2 receptor agonists combined with anticholinergic drugs%children asthma
目的:评价β2受体激动剂、抗胆碱能药物以及β2受体激动剂联合抗胆碱能药物在治疗急诊儿童急性哮喘中的应用。方法搜索自建库至今 Pubmed、Embase和中国科技期刊数据库关于抗胆碱能药物、β2受体激动剂在治疗儿童急性哮喘中的随机对照试验,对纳入的研究进行质量评价与数据提取,采用Revman 5.0.2软件进行统计分析。结果β2受体激动剂组在治疗失败率和接受治疗60 min后1 s用力呼气容积(FEV1)变化量占预计值的百分比方面明显优于抗胆碱能药物治疗组,OR及95%可信区间(95% CI)分别为2.27(95% CI:1.08~4.75)和12.6(95% C I:6.61~18.59),在住院率方面两组差异无统计学意义( P>0.05),OR及95% C I为1.11(95% C I:0.66~1.86)。β2受体激动剂联合抗胆碱能药物组在治疗失败率、住院率和接受治疗60min后FEV1变化量占预计值的百分比方面明显优于抗胆碱能药物治疗组,OR及95% C I分别为3.67(95% C I:1.41~9.50)、2.28(95% C I:1.39~3.73)、10.65(95% C I:5.87~15.43)。结论β2受体激动剂以及β2受体激动剂联合抗胆碱能药物在治疗急诊儿童急性哮喘中的效果明显优于单独使用抗胆碱能药物。
目的:評價β2受體激動劑、抗膽堿能藥物以及β2受體激動劑聯閤抗膽堿能藥物在治療急診兒童急性哮喘中的應用。方法搜索自建庫至今 Pubmed、Embase和中國科技期刊數據庫關于抗膽堿能藥物、β2受體激動劑在治療兒童急性哮喘中的隨機對照試驗,對納入的研究進行質量評價與數據提取,採用Revman 5.0.2軟件進行統計分析。結果β2受體激動劑組在治療失敗率和接受治療60 min後1 s用力呼氣容積(FEV1)變化量佔預計值的百分比方麵明顯優于抗膽堿能藥物治療組,OR及95%可信區間(95% CI)分彆為2.27(95% CI:1.08~4.75)和12.6(95% C I:6.61~18.59),在住院率方麵兩組差異無統計學意義( P>0.05),OR及95% C I為1.11(95% C I:0.66~1.86)。β2受體激動劑聯閤抗膽堿能藥物組在治療失敗率、住院率和接受治療60min後FEV1變化量佔預計值的百分比方麵明顯優于抗膽堿能藥物治療組,OR及95% C I分彆為3.67(95% C I:1.41~9.50)、2.28(95% C I:1.39~3.73)、10.65(95% C I:5.87~15.43)。結論β2受體激動劑以及β2受體激動劑聯閤抗膽堿能藥物在治療急診兒童急性哮喘中的效果明顯優于單獨使用抗膽堿能藥物。
목적:평개β2수체격동제、항담감능약물이급β2수체격동제연합항담감능약물재치료급진인동급성효천중적응용。방법수색자건고지금 Pubmed、Embase화중국과기기간수거고관우항담감능약물、β2수체격동제재치료인동급성효천중적수궤대조시험,대납입적연구진행질량평개여수거제취,채용Revman 5.0.2연건진행통계분석。결과β2수체격동제조재치료실패솔화접수치료60 min후1 s용력호기용적(FEV1)변화량점예계치적백분비방면명현우우항담감능약물치료조,OR급95%가신구간(95% CI)분별위2.27(95% CI:1.08~4.75)화12.6(95% C I:6.61~18.59),재주원솔방면량조차이무통계학의의( P>0.05),OR급95% C I위1.11(95% C I:0.66~1.86)。β2수체격동제연합항담감능약물조재치료실패솔、주원솔화접수치료60min후FEV1변화량점예계치적백분비방면명현우우항담감능약물치료조,OR급95% C I분별위3.67(95% C I:1.41~9.50)、2.28(95% C I:1.39~3.73)、10.65(95% C I:5.87~15.43)。결론β2수체격동제이급β2수체격동제연합항담감능약물재치료급진인동급성효천중적효과명현우우단독사용항담감능약물。
Objective To evaluate the application of β2 receptor agonists ,anticholinergic drugs and β2 receptor agonists combined with anticholinergic drugs in children acute asthma .Methods The randomized controlled trials (RCTs)on the application ofβ2 receptor agonists and anticholinergic drugs in children asthma were retrieved from the Pubmed ,Embase and CJFD(from database establishment to now ) .The included RCTs were performed the quality e-valuation and data extraction .The Revman 5 .0 .2 software was adopted to conduct the statistical analysis .Results 14 RCTs involving 1028 patients were included .β2 receptor agonists was significantly superior to the anticholinergic drugs in the aspects of the treatment failure rate and the percentage of FEV 1 variation to the expected value at 60 min after treatment ,OR and 95% CI were 2 .27(95% CI:1 .08 -4 .75)and 12 .6(95% CI:6 .61 -18 .59) ,the hospitaliza-tion rate had no statistical difference between the two groups (P>0 .05) ,OR and 95% CI were 1 .11(95% CI:0 .66-1 .86) .β2 receptor agonists combined with anticholinergic drugs was significantly superior to the anticholinergic drugs treatment group in the aspects of the treatment failure rate ,hospitalization rate and the percentage of FEV 1 variation to the expected value at 60 min after treatment ,OR and 95% CI were 3 .67(95% CI:1 .41 -9 .50) ,2 .28(95% CI:1 .39-3 .73)and 10 .65(95% CI:5 .87 -15 .43) .Conclusion β2 receptor agonists and β2 receptor agonists combined with anticholinergic drugs have better efficacy on children acute asthma than single anticholinergic drugs .